After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NYSE-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Ginkgo Bioworks Holdings Inc is $509.77M. A total of 1.32 million shares were traded on the day, compared to an average of 1.35M shares.
In the most recent transaction, Che Austin bought 99 shares of DNA for 7.41 per share on Nov 25 ’24. In a previous transaction on Nov 22 ’24, Che Austin bought 99 shares at 6.64 per share.
Among the insiders who bought shares, Che Austin acquired of 99 shares on Nov 21 ’24 at a per-share price of $6.46. In another insider transaction, Che Austin bought 99 shares at $6.46 per share on Nov 20 ’24.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, DNA has a high of $75.20 and a low of $5.26.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. DNA’s latest balance sheet shows that the firm has $1.55B in Cash & Short Term Investments as of fiscal 2021. There were $23.03M in debt and $134.76M in liabilities at the time. Its Book Value Per Share was $15.93, while its Total Shareholder’s Equity was $1.57B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DNA is Buy with a score of 2.17.
